Conference on Biosimilars Congregation 2012

Navi Mumbai, India (PressExposure) January 04, 2012 -- promote a new conference on "Biosimilars Congregation 2012" which Identifying issues and solutions surrounding biosimiliars and clinical trials.

Conference on Biosimilars Congregation 2012 to be Held at Hilton London Euston Hotel, London UK on February 24th 2012

Conference Intro:

According to Global Industry Analysts Inc.. the global market for biosimilars is forecast to reach US$4.8 billion by the year 2015. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market.

The pharmaceutical industry is facing a tough road ahead in the future marketplace. Though pharmaceuticals remain the most cost-effective healthcare intervention, everyone should bring about a significant transformation in their organizations to realize a glorious future. Biosimilars remains to be a provocative subject in the global pharmaceutical industry. However, with the sector promising significant cost savings to the industry, several major markets are welcoming biosimilar legislations for the development of biosimilars. Consequently, biosimilars are expected to grow into a multi-billion dollar market in future

Key themes discussed at this Summit:

Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease

How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars

How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?

Identifying issues and solutions surrounding biosimiliars and clinical trials.

Next generation monoclonal antibody development and clinical challenges with biosimilar drug development

Overcoming pricing and reimbursement challenges to maximise the ROI

Determining the right investments & potential returns from Biosimilars

Commercial challenges and opportunities - strategies to develop Biosimilars

Biosimilars Vs Bio-betters - positioning for a new market with lucrative prospects

Learn to implement best practices through recent successful strategies and business models - real time case studies

Analyze the FDA''''''''s current view of biosimilars

The developing regulatory framework in advanced and developing markets

EMA Regulatory Opinions on Treatment of mAbs

Critical issues in demonstrating biosimilarity and maintaining diligent quality control

Be part of a major networking opportunity

For more information kindly visit :


Contact us at :

Company Profiles And Conferences

Phone : +91 22 2756 1536

Fax : +91 22 2757 9131

E-mail :

Website :

About Company Profiles And Conferences

Search thousands of company profiles, SWOT analysis reports and company financials. Search by industry sector, or simply search all company profiles by company name. contains one of the world's largest collections of company insight and company profiles from leading global market report publishers and analysts. Global brands rely on for their strategic company insight and company profile needs.

Press Release Source:

Press Release Submitted On: January 04, 2012 at 5:34 am
This article has been viewed 28307 time(s).